Safety and efficacy with drug-eluting stent in ST-segment elevation and non-ST-segment elevation myocardial infarction

Chang Bum Park, Cheol Whan Lee, Bong Ki Lee, Young Hak Kim, Myeongki Hong, Jae Joong Kim, Seong Wook Park, Seung Jung Park

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Drug-eluting stents (DES) have been shown to reduce the need for repeat revascularization compared with bare metal stents (BMS). However, there is little information regarding the safety and long-term efficacy of DES in patients with acute myocardial infarction (AMI). Hypothesis: The aim of this study was to evaluate the safety and efficacy of DES in patients with AMI. Methods: Data from 211 consecutive patients with AMI treated with DES were compared with those from 228 consecutive patients with AMI treated with BMS. All patients were treated within 7 days of symptom onset. The incidence of major adverse cardiovascular events ([MACE]: death, reinfarction, and target vessel revascularization) was evaluated at 30 days and 1 year. Results: Baseline clinical and angiographic characteristics were similar for both stent groups. However, patients who received DES had longer lesion lengths (23.0 ± 12.7 vs. 18.8 ± 10.6 mm, respectively; p < 0.001) and smaller reference diameters (2.97 ± 0.52 vs. 3.19 ± 0.63 mm, respectively, p < 0.001). At 30 days, the incidence rates of MACE (DES vs. BMS: 2.2 vs. 1.9%, p = 1.000) and stent thrombosis (BMS vs. DES: 0.9 vs. 1.7%; p = 0.434) did not differ significantly between the groups. At 1 year, patients with DES had a lower rate of MACE (BMS vs. DES: 14.0 vs. 6.6%; p = 0.011) primarily due to a lower target vessel revascularization rate (BMS vs. DES: 9.6 vs. 4.8%; p = 0.028). Conclusions: The DES appear to be superior to the BMS in reducing the risk of MACE in patients with AMI.

Original languageEnglish
Pages (from-to)199-203
Number of pages5
JournalClinical Cardiology
Volume29
Issue number5
DOIs
Publication statusPublished - 2006 May 1

Fingerprint

Drug-Eluting Stents
Stents
Safety
Metals
Myocardial Infarction
Non-ST Elevated Myocardial Infarction
Cardiovascular Agents
Incidence
Thrombosis

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Park, Chang Bum ; Lee, Cheol Whan ; Lee, Bong Ki ; Kim, Young Hak ; Hong, Myeongki ; Kim, Jae Joong ; Park, Seong Wook ; Park, Seung Jung. / Safety and efficacy with drug-eluting stent in ST-segment elevation and non-ST-segment elevation myocardial infarction. In: Clinical Cardiology. 2006 ; Vol. 29, No. 5. pp. 199-203.
@article{e8938a24484a491badbd11964841d734,
title = "Safety and efficacy with drug-eluting stent in ST-segment elevation and non-ST-segment elevation myocardial infarction",
abstract = "Background: Drug-eluting stents (DES) have been shown to reduce the need for repeat revascularization compared with bare metal stents (BMS). However, there is little information regarding the safety and long-term efficacy of DES in patients with acute myocardial infarction (AMI). Hypothesis: The aim of this study was to evaluate the safety and efficacy of DES in patients with AMI. Methods: Data from 211 consecutive patients with AMI treated with DES were compared with those from 228 consecutive patients with AMI treated with BMS. All patients were treated within 7 days of symptom onset. The incidence of major adverse cardiovascular events ([MACE]: death, reinfarction, and target vessel revascularization) was evaluated at 30 days and 1 year. Results: Baseline clinical and angiographic characteristics were similar for both stent groups. However, patients who received DES had longer lesion lengths (23.0 ± 12.7 vs. 18.8 ± 10.6 mm, respectively; p < 0.001) and smaller reference diameters (2.97 ± 0.52 vs. 3.19 ± 0.63 mm, respectively, p < 0.001). At 30 days, the incidence rates of MACE (DES vs. BMS: 2.2 vs. 1.9{\%}, p = 1.000) and stent thrombosis (BMS vs. DES: 0.9 vs. 1.7{\%}; p = 0.434) did not differ significantly between the groups. At 1 year, patients with DES had a lower rate of MACE (BMS vs. DES: 14.0 vs. 6.6{\%}; p = 0.011) primarily due to a lower target vessel revascularization rate (BMS vs. DES: 9.6 vs. 4.8{\%}; p = 0.028). Conclusions: The DES appear to be superior to the BMS in reducing the risk of MACE in patients with AMI.",
author = "Park, {Chang Bum} and Lee, {Cheol Whan} and Lee, {Bong Ki} and Kim, {Young Hak} and Myeongki Hong and Kim, {Jae Joong} and Park, {Seong Wook} and Park, {Seung Jung}",
year = "2006",
month = "5",
day = "1",
doi = "10.1002/clc.4960290506",
language = "English",
volume = "29",
pages = "199--203",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

Safety and efficacy with drug-eluting stent in ST-segment elevation and non-ST-segment elevation myocardial infarction. / Park, Chang Bum; Lee, Cheol Whan; Lee, Bong Ki; Kim, Young Hak; Hong, Myeongki; Kim, Jae Joong; Park, Seong Wook; Park, Seung Jung.

In: Clinical Cardiology, Vol. 29, No. 5, 01.05.2006, p. 199-203.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and efficacy with drug-eluting stent in ST-segment elevation and non-ST-segment elevation myocardial infarction

AU - Park, Chang Bum

AU - Lee, Cheol Whan

AU - Lee, Bong Ki

AU - Kim, Young Hak

AU - Hong, Myeongki

AU - Kim, Jae Joong

AU - Park, Seong Wook

AU - Park, Seung Jung

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Background: Drug-eluting stents (DES) have been shown to reduce the need for repeat revascularization compared with bare metal stents (BMS). However, there is little information regarding the safety and long-term efficacy of DES in patients with acute myocardial infarction (AMI). Hypothesis: The aim of this study was to evaluate the safety and efficacy of DES in patients with AMI. Methods: Data from 211 consecutive patients with AMI treated with DES were compared with those from 228 consecutive patients with AMI treated with BMS. All patients were treated within 7 days of symptom onset. The incidence of major adverse cardiovascular events ([MACE]: death, reinfarction, and target vessel revascularization) was evaluated at 30 days and 1 year. Results: Baseline clinical and angiographic characteristics were similar for both stent groups. However, patients who received DES had longer lesion lengths (23.0 ± 12.7 vs. 18.8 ± 10.6 mm, respectively; p < 0.001) and smaller reference diameters (2.97 ± 0.52 vs. 3.19 ± 0.63 mm, respectively, p < 0.001). At 30 days, the incidence rates of MACE (DES vs. BMS: 2.2 vs. 1.9%, p = 1.000) and stent thrombosis (BMS vs. DES: 0.9 vs. 1.7%; p = 0.434) did not differ significantly between the groups. At 1 year, patients with DES had a lower rate of MACE (BMS vs. DES: 14.0 vs. 6.6%; p = 0.011) primarily due to a lower target vessel revascularization rate (BMS vs. DES: 9.6 vs. 4.8%; p = 0.028). Conclusions: The DES appear to be superior to the BMS in reducing the risk of MACE in patients with AMI.

AB - Background: Drug-eluting stents (DES) have been shown to reduce the need for repeat revascularization compared with bare metal stents (BMS). However, there is little information regarding the safety and long-term efficacy of DES in patients with acute myocardial infarction (AMI). Hypothesis: The aim of this study was to evaluate the safety and efficacy of DES in patients with AMI. Methods: Data from 211 consecutive patients with AMI treated with DES were compared with those from 228 consecutive patients with AMI treated with BMS. All patients were treated within 7 days of symptom onset. The incidence of major adverse cardiovascular events ([MACE]: death, reinfarction, and target vessel revascularization) was evaluated at 30 days and 1 year. Results: Baseline clinical and angiographic characteristics were similar for both stent groups. However, patients who received DES had longer lesion lengths (23.0 ± 12.7 vs. 18.8 ± 10.6 mm, respectively; p < 0.001) and smaller reference diameters (2.97 ± 0.52 vs. 3.19 ± 0.63 mm, respectively, p < 0.001). At 30 days, the incidence rates of MACE (DES vs. BMS: 2.2 vs. 1.9%, p = 1.000) and stent thrombosis (BMS vs. DES: 0.9 vs. 1.7%; p = 0.434) did not differ significantly between the groups. At 1 year, patients with DES had a lower rate of MACE (BMS vs. DES: 14.0 vs. 6.6%; p = 0.011) primarily due to a lower target vessel revascularization rate (BMS vs. DES: 9.6 vs. 4.8%; p = 0.028). Conclusions: The DES appear to be superior to the BMS in reducing the risk of MACE in patients with AMI.

UR - http://www.scopus.com/inward/record.url?scp=33646507906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646507906&partnerID=8YFLogxK

U2 - 10.1002/clc.4960290506

DO - 10.1002/clc.4960290506

M3 - Article

VL - 29

SP - 199

EP - 203

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 5

ER -